New research, led by scientists from the Seaver Autism Center for Research and Treatment at Mount Sinai and published in ...
A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine whether prostate cancers are susceptible to a type of cell death known as ...
As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...
New research, led by scientists from the Seaver Autism Center for Research and Treatment at Mount Sinai and published June 28 ...
ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...
A novel prime editing tool has unraveled some of the mysteries of fungi and identified compounds with promising anti-cancer ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) ...
Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...
An experimental drug that targets the TDP-43 protein offers hope for treating Amyotrophic Lateral Sclerosis (ALS), a condition that still lacks both a treatment and a cure. ALS received widespread ...
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Ionis Pharmaceuticals IONS announced that it has completed enrollment in cohort 1 of the phase III REVEAL study, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results